$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000145983923000020 Filed on March 02, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$32.71M	$31.95M	$106.4M
YoY Change	45.76%	26.65%	18.03%
Cost Of Revenue	$5.924M	$5.089M	$15.71M
YoY Change	98.59%	50.79%	50.6%
Gross Profit	$26.78M	$26.86M	$90.70M
YoY Change	37.66%	22.92%	13.77%
Gross Profit Margin	81.89%	84.07%	85.24%
Selling, General & Admin	$34.79M	$34.68M	$136.7M
YoY Change	6.24%	5.93%	14.91%
% of Gross Profit	129.88%	129.09%	150.69%
Research & Development	$3.291M	$3.480M	$13.63M
YoY Change	-8.07%	14.14%	9.53%
% of Gross Profit	12.29%	12.95%	15.02%
Depreciation & Amortization	$1.086M	$1.002M	$3.452M
YoY Change	52.31%	54.15%	65.48%
% of Gross Profit	4.05%	3.73%	3.81%
Operating Expenses	$38.08M	$38.16M	$150.3M
YoY Change	4.83%	6.63%	14.4%
Operating Profit	-$11.29M	-$11.29M	-$59.61M
YoY Change	-33.05%	-18.93%	15.36%
Interest Expense	$838.0K	$568.0K	$2.819M
YoY Change	49.38%	-206.57%	-47.46%
% of Operating Profit
Other Income/Expense, Net	$74.00K	$251.0K	-$132.0K
YoY Change	-237.04%	-2030.77%	-147.65%
Pretax Income	-$11.13M	-$11.18M	-$61.40M
YoY Change	-36.1%	-22.81%	7.65%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$11.13M	-$11.18M	-$61.26M
YoY Change	-36.1%	-22.81%	8.28%
Net Earnings / Revenue	-34.01%	-34.97%	-57.57%
Basic Earnings Per Share	-$0.32		-$1.79
Diluted Earnings Per Share	-$0.32	-$0.32	-$1.79
COMMON SHARES
Basic Shares Outstanding	34.99M shares	34.50M shares	34.20M shares
Diluted Shares Outstanding	34.92M shares		34.20M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.97M	$97.29M	$97.29M
YoY Change	-34.24%	-33.81%	-33.81%
Cash & Equivalents	$22.97M	$20.72M	$20.72M
Short-Term Investments	$63.00M	$76.57M	$76.57M
Other Short-Term Assets	$2.045M	$2.365M	$2.365M
YoY Change	-34.93%	-24.75%	-24.75%
Inventory	$17.79M	$17.28M	$17.28M
Prepaid Expenses
Receivables	$22.60M	$20.67M	$20.67M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$128.4M	$137.6M	$137.6M
YoY Change	-20.38%	-21.75%	-21.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.63M	$15.56M	$19.57M
YoY Change	61.82%	73.09%	37.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$374.0K	$375.0K	$375.0K
YoY Change	-5.32%	-6.25%	-6.25%
Total Long-Term Assets	$20.68M	$19.94M	$19.94M
YoY Change	32.63%	36.21%	36.21%
TOTAL ASSETS
Total Short-Term Assets	$128.4M	$137.6M	$137.6M
Total Long-Term Assets	$20.68M	$19.94M	$19.94M
Total Assets	$149.1M	$157.6M	$157.6M
YoY Change	-15.7%	-17.3%	-17.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.331M	$6.279M	$6.279M
YoY Change	6.66%	96.34%	96.34%
Accrued Expenses	$9.896M	$13.51M	$13.11M
YoY Change	7.93%	9.37%	5.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$16.63M	$21.18M	$21.18M
YoY Change	7.6%	25.39%	25.39%
LONG-TERM LIABILITIES
Long-Term Debt	$35.94M	$35.17M	$35.17M
YoY Change	2.61%	0.57%	0.57%
Other Long-Term Liabilities	$26.00K	$30.00K	$2.901M
YoY Change	-42.22%	-47.37%	-31.3%
Total Long-Term Liabilities	$35.96M	$35.20M	$38.07M
YoY Change	2.55%	0.49%	-2.87%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.63M	$21.18M	$21.18M
Total Long-Term Liabilities	$35.96M	$35.20M	$38.07M
Total Liabilities	$55.12M	$59.25M	$59.25M
YoY Change	1.3%	5.64%	5.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$368.2M	-$357.1M
YoY Change	17.55%	20.71%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$93.96M	$98.30M	$98.30M
YoY Change
Total Liabilities & Shareholders Equity	$149.1M	$157.6M	$157.6M
YoY Change	-15.7%	-17.3%	-17.3%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$11.13M	-$11.18M	-$61.26M
YoY Change	-36.1%	-22.81%	8.28%
Depreciation, Depletion And Amortization	$1.086M	$1.002M	$3.452M
YoY Change	52.31%	54.15%	65.48%
Cash From Operating Activities	-$10.75M	-$6.775M	-$41.66M
YoY Change	-20.42%	-46.71%	5.37%
INVESTING ACTIVITIES
Capital Expenditures	$2.579M	$1.660M	$9.507M
YoY Change	13.41%	-193.52%	48.8%
Acquisitions
YoY Change
Other Investing Activities	$14.28M	$1.749M	$6.692M
YoY Change	-170.24%	-89.8%	-88.46%
Cash From Investing Activities	$11.70M	$89.00K	-$2.815M
YoY Change	-151.76%	-99.42%	-105.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$35.28M		$0.00
YoY Change			-100.0%
Cash From Financing Activities	$1.205M	693.0K	$2.197M
YoY Change	613.02%	-31.72%	-228.4%
NET CHANGE
Cash From Operating Activities	-$10.75M	-6.775M	-$41.66M
Cash From Investing Activities	$11.70M	89.00K	-$2.815M
Cash From Financing Activities	$1.205M	693.0K	$2.197M
Net Change In Cash	$2.252M	-5.993M	-$42.70M
YoY Change	-106.24%	-262.9%	-534.05%
FREE CASH FLOW
Cash From Operating Activities	-$10.75M	-$6.775M	-$41.66M
Capital Expenditures	$2.579M	$1.660M	$9.507M
Free Cash Flow	-$13.33M	-$8.435M	-$51.16M
YoY Change	-15.55%	-22.89%	11.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38701
CY2022	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2216351
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	471 El Camino Real
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95050
CY2022	dei	City Area Code CityAreaCode	408
CY2022	dei	Local Phone Number LocalPhoneNumber	207-0700
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	SIBN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	443000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34985640	shares
CY2022	dei	Auditor Firm AuditorFirmId	238
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	San Jose, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20717000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63419000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76573000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83560000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	400000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	264000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20674000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14246000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	17282000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	11498000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2365000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3143000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	137611000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	175866000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15564000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8992000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4002000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5248000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	375000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	400000	usd
CY2022Q4	us-gaap	Assets Assets	157552000	usd
CY2021Q4	us-gaap	Assets Assets	190506000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6279000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3198000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13511000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12353000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1388000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1339000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21178000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16890000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35171000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34973000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2871000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4166000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	57000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	59250000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	56086000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34731577	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34731577	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33674085	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33674085	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	455172000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	429914000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	232000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	352000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-357105000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-295849000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98302000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134420000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157552000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	190506000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106409000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90152000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15705000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10428000	usd
CY2022	us-gaap	Gross Profit GrossProfit	90704000	usd
CY2021	us-gaap	Gross Profit GrossProfit	79724000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	107726000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	93884000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13627000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12441000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28960000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25069000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	150313000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	131394000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-59609000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-51670000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1304000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	186000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2819000	usd
CY2021	us-gaap	Interest Expense InterestExpense	5365000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-132000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	277000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-56572000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-65000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-31000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-55000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-141000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61376000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56744000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34201824	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34201824	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33145930	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33145930	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	169363000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2565000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2343000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16866000	usd
CY2021	sibn	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions	27000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-141000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-31000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-56572000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134420000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	379000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1818000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23061000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-55000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-65000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	98302000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-56572000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	23061000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	16866000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3452000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2086000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-229000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1294000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41655000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39533000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	198000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	288000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1848000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-153000	usd
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-399000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6479000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	569000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5709000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5784000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-810000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	594000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2529000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-532000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1207000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1723000	usd
CY2022	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	126200000	usd
CY2021	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	159990000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	119508000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	102021000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9507000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6389000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2815000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	51580000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	35000000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	41000000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	111000	usd
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
CY2021	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	508000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	379000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2565000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1818000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2343000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2197000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1711000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-429000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-498000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42702000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9838000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63419000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53581000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20717000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63419000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2621000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	3230000	usd
CY2022	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	0	usd
CY2021	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	27000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1115000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	509000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	The Company and Nature of Business<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The Company introduced its first generation iFuse implant in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world. The second generation iFuse implant, iFuse 3-D, was introduced in 2017 followed by iFuse-TORQ in 2021 and iFuse Bedrock Granite in 2022.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to continuing risk and uncertainties as a result of the COVID-19 pandemic, and is closely monitoring the impact of the pandemic on all aspects of its business, including the impacts on its customers, patients that would benefit from procedures involving the Company's products, employees, suppliers, vendors, business partners and distribution channels. Economies worldwide continue to be negatively impacted by the COVID-19 pandemic, in particular with recurrent mutations of the virus, despite advances in vaccines, and the Company anticipates these disruptions will continue. Certain of the Company’s third-party suppliers have faced delays, product shortages and rising costs resulting from disruptions in the global supply chain, resulting in shop capacity issues impacting lead-times and quantities of implants and instruments available. As a result, the Company is continuing to work closely with its manufacturing partners and suppliers, as well as determining alternative sourcing strategies to enable the Company to source key components and maintain appropriate inventory levels to meet customer demand. As such the Company's future results of operations and liquidity could be adversely impacted by a variety of factors related to the COVID-19 pandemic, including those discussed in the section entitled "Risk Factors" in this report. As of the date of issuance of these consolidated financial statements, the extent to which the COVID-19 pandemic and global supply chain issues may materially impact the Company's financial condition, liquidity, or results of operations remains uncertain.</span></div>
CY2022	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Significant accounting estimates and management judgments reflected in the consolidated financial </span>statements primarily includes the fair value of performance-based restricted stock unit awards. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	106409000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	90152000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and marketable securities. The Company’s cash and marketable securities are deposited with financial institutions in the U.S. and in Europe. The majority of the Company’s cash and marketable securities are deposited with a single financial institution in the U.S. Deposits in this institution exceed the amount of insurance provided on such deposits. The Company has not experienced any net losses on its deposits of cash and marketable securities.</span></div>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	264000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	263000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	14000	usd
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	13000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	264000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	sibn	Standard Product Warranty Term StandardProductWarrantyTerm	P1Y
CY2022	sibn	Sales Credit Reserve Period SalesCreditReservePeriod	P1Y
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1600000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	1200000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8002000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	8002000	usd
CY2022Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	76674000	usd
CY2022Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	108000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76573000	usd
CY2022Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	84676000	usd
CY2022Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	usd
CY2022Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	108000	usd
CY2022Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	84575000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	57829000	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	57829000	usd
CY2021Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	83595000	usd
CY2021Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	4000	usd
CY2021Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	39000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	83560000	usd
CY2021Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	141424000	usd
CY2021Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4000	usd
CY2021Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	39000	usd
CY2021Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	141389000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	200000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15600000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1700000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25771000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15958000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10207000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6966000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15564000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8992000	usd
CY2022	us-gaap	Depreciation Depreciation	3400000	usd
CY2021	us-gaap	Depreciation Depreciation	2100000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11365000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10055000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	355000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	995000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1791000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1303000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13511000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12353000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1599000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1181000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	461000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	266000	usd
CY2022	us-gaap	Lease Cost LeaseCost	2060000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1447000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1600000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1225000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	127000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2896000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M23D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0577
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0575
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1590000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1513000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1004000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	529000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4645000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	386000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4259000	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	800000	usd
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	1200000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	73000	usd
CY2021Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	100000	usd
CY2022Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	456000	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	627000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	35171000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	34973000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	35171000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34973000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	4861000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11667000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11667000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	7505000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	35700000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34731577	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34731577	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33674085	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33674085	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2405957	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.54
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	369375	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.94
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	27069	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.85
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2009513	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.73
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	80571	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.70
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	25601	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.05
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1903341	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.82
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y11M1D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	12919000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1892990	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.75
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y10M28D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	12919000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1901995	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.81
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y11M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	12919000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1000000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	8100000	usd
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1903341	shares
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y10M28D
CY2022Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.82
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1892990	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.75
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	22000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23061000	usd
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	170717	shares
CY2021	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	147295	shares
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1800000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2300000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16866000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-56572000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34201824	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34201824	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33145930	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33145930	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.79
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4106213	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3755421	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61396000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-57035000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	140000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	463000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-61256000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-56572000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	13085000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12994000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2997000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1878000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-92000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	461000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15990000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15333000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15990000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15333000	usd
CY2022	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	usd
CY2021	sibn	Deferred Income Tax Expense Benefit Net Of Valuation Allowance DeferredIncomeTaxExpenseBenefitNetOfValuationAllowance	0	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.033
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.261
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.271
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.003
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.017
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	77057000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	66015000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4464000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3837000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2616000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1994000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4447000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	3995000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	263000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	152000	usd
CY2022Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	3378000	usd
CY2021Q4	sibn	Deferred Tax Assets Depreciation And Amortization DeferredTaxAssetsDepreciationAndAmortization	2728000	usd
CY2022Q4	sibn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1079000	usd
CY2021Q4	sibn	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1376000	usd
CY2022Q4	sibn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2486000	usd
CY2021Q4	sibn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	95790000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	80097000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1014000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1311000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1014000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1311000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94776000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78786000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021	sibn	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	817000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	301000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78786000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63453000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15990000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15333000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94776000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78786000	usd
CY2022Q4	sibn	Operating Loss Carryforwards Limited OperatingLossCarryforwardsLimited	1400000	usd
CY2022Q4	sibn	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	2500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2655000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1513000	usd
CY2022	sibn	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-12000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	325000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2944000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2655000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001459839-23-000020-index-headers.html	Edgar Link	pending
0001459839-23-000020-index.html	Edgar Link	pending
0001459839-23-000020.txt	Edgar Link	pending
0001459839-23-000020-xbrl.zip	Edgar Link	pending
confidentialmarkupsvb_-x.htm	Edgar Link	pending
confidentialmarkupsvb_-x001.jpg	Edgar Link	pending
confidentialmarkupsvb_-x002.jpg	Edgar Link	pending
confidentialmarkupsvb_-x003.jpg	Edgar Link	pending
confidentialmarkupsvb_-x004.jpg	Edgar Link	pending
confidentialmarkupsvb_-x005.jpg	Edgar Link	pending
confidentialmarkupsvb_-x006.jpg	Edgar Link	pending
confidentialmarkupsvb_-x007.jpg	Edgar Link	pending
confidentialmarkupsvb_-x008.jpg	Edgar Link	pending
confidentialmarkupsvb_-x009.jpg	Edgar Link	pending
confidentialmarkupsvb_-x010.jpg	Edgar Link	pending
confidentialmarkupsvb_-x011.jpg	Edgar Link	pending
confidentialmarkupsvb_-x012.jpg	Edgar Link	pending
confidentialmarkupsvb_-x013.jpg	Edgar Link	pending
confidentialmarkupsvb_-x014.jpg	Edgar Link	pending
confidentialmarkupsvb_-x015.jpg	Edgar Link	pending
confidentialmarkupsvb_-x016.jpg	Edgar Link	pending
confidentialmarkupsvb_-x017.jpg	Edgar Link	pending
confidentialmarkupsvb_-x018.jpg	Edgar Link	pending
confidentialmarkupsvb_-x019.jpg	Edgar Link	pending
confidentialmarkupsvb_-x020.jpg	Edgar Link	pending
confidentialmarkupsvb_-x021.jpg	Edgar Link	pending
confidentialmarkupsvb_-x022.jpg	Edgar Link	pending
confidentialmarkupsvb_-x023.jpg	Edgar Link	pending
confidentialmarkupsvb_-x024.jpg	Edgar Link	pending
confidentialmarkupsvb_-x025.jpg	Edgar Link	pending
confidentialmarkupsvb_-x026.jpg	Edgar Link	pending
confidentialmarkupsvb_-x027.jpg	Edgar Link	pending
confidentialmarkupsvb_-x028.jpg	Edgar Link	pending
confidentialmarkupsvb_-x029.jpg	Edgar Link	pending
confidentialmarkupsvb_-x030.jpg	Edgar Link	pending
confidentialmarkupsvb_-x031.jpg	Edgar Link	pending
confidentialmarkupsvb_-x032.jpg	Edgar Link	pending
confidentialmarkupsvb_-x033.jpg	Edgar Link	pending
confidentialmarkupsvb_-x034.jpg	Edgar Link	pending
confidentialmarkupsvb_-x035.jpg	Edgar Link	pending
confidentialmarkupsvb_-x036.jpg	Edgar Link	pending
confidentialmarkupsvb_-x037.jpg	Edgar Link	pending
confidentialmarkupsvb_-x038.jpg	Edgar Link	pending
confidentialmarkupsvb_-x039.jpg	Edgar Link	pending
confidentialmarkupsvb_-x040.jpg	Edgar Link	pending
confidentialmarkupsvb_-x041.jpg	Edgar Link	pending
confidentialmarkupsvb_-x042.jpg	Edgar Link	pending
confidentialmarkupsvb_-x043.jpg	Edgar Link	pending
confidentialmarkupsvb_-x044.jpg	Edgar Link	pending
confidentialmarkupsvb_-x045.jpg	Edgar Link	pending
confidentialmarkupsvb_-x046.jpg	Edgar Link	pending
confidentialmarkupsvb_-x047.jpg	Edgar Link	pending
confidentialmarkupsvb_-x048.jpg	Edgar Link	pending
confidentialmarkupsvb_-x049.jpg	Edgar Link	pending
confidentialmarkupsvb_-x050.jpg	Edgar Link	pending
confidentialmarkupsvb_-x051.jpg	Edgar Link	pending
confidentialmarkupsvb_-x052.jpg	Edgar Link	pending
confidentialmarkupsvb_-x053.jpg	Edgar Link	pending
confidentialmarkupsvb_-x054.jpg	Edgar Link	pending
confidentialmarkupsvb_-x055.jpg	Edgar Link	pending
confidentialmarkupsvb_-x056.jpg	Edgar Link	pending
confidentialmarkupsvb_-x057.jpg	Edgar Link	pending
confidentialmarkupsvb_-x058.jpg	Edgar Link	pending
confidentialmarkupsvb_-x059.jpg	Edgar Link	pending
confidentialmarkupsvb_-x060.jpg	Edgar Link	pending
confidentialmarkupsvb_-x061.jpg	Edgar Link	pending
confidentialmarkupsvb_-x062.jpg	Edgar Link	pending
confidentialmarkupsvb_-x063.jpg	Edgar Link	pending
confidentialmarkupsvb_-x064.jpg	Edgar Link	pending
confidentialmarkupsvb_-x065.jpg	Edgar Link	pending
confidentialmarkupsvb_-x066.jpg	Edgar Link	pending
confidentialmarkupsvb_-x067.jpg	Edgar Link	pending
confidentialmarkupsvb_-x068.jpg	Edgar Link	pending
confidentialmarkupsvb_-x069.jpg	Edgar Link	pending
confidentialmarkupsvb_-x070.jpg	Edgar Link	pending
confidentialmarkupsvb_-x071.jpg	Edgar Link	pending
confidentialmarkupsvb_-x072.jpg	Edgar Link	pending
confidentialmarkupsvb_-x073.jpg	Edgar Link	pending
confidentialmarkupsvb_-x074.jpg	Edgar Link	pending
confidentialmarkupsvb_-x075.jpg	Edgar Link	pending
confidentialmarkupsvb_-x076.jpg	Edgar Link	pending
confidentialmarkupsvb_-x077.jpg	Edgar Link	pending
confidentialmarkupsvb_-x078.jpg	Edgar Link	pending
confidentialmarkupsvb_-x079.jpg	Edgar Link	pending
confidentialmarkupsvb_-x080.jpg	Edgar Link	pending
confidentialmarkupsvb_-x081.jpg	Edgar Link	pending
confidentialmarkupsvb_-x082.jpg	Edgar Link	pending
confidentialmarkupsvb_-x083.jpg	Edgar Link	pending
confidentialmarkupsvb_-x084.jpg	Edgar Link	pending
confidentialmarkupsvb_-x085.jpg	Edgar Link	pending
confidentialmarkupsvb_-x086.jpg	Edgar Link	pending
confidentialmarkupsvb_-x087.jpg	Edgar Link	pending
confidentialmarkupsvb_-x088.jpg	Edgar Link	pending
confidentialmarkupsvb_-x089.jpg	Edgar Link	pending
confidentialmarkupsvb_-x090.jpg	Edgar Link	pending
confidentialmarkupsvb_-x091.jpg	Edgar Link	pending
confidentialmarkupsvb_-x092.jpg	Edgar Link	pending
confidentialmarkupsvb_-x093.jpg	Edgar Link	pending
confidentialmarkupsvb_-x094.jpg	Edgar Link	pending
confidentialmarkupsvb_-x095.jpg	Edgar Link	pending
confidentialmarkupsvb_-x096.jpg	Edgar Link	pending
confidentialmarkupsvb_-x097.jpg	Edgar Link	pending
confidentialmarkupsvb_-x098.jpg	Edgar Link	pending
confidentialmarkupsvb_-x099.jpg	Edgar Link	pending
confidentialmarkupsvb_-x100.jpg	Edgar Link	pending
confidentialmarkupsvb_-x101.jpg	Edgar Link	pending
confidentialmarkupsvb_-x102.jpg	Edgar Link	pending
confidentialmarkupsvb_-x103.jpg	Edgar Link	pending
confidentialmarkupsvb_-x104.jpg	Edgar Link	pending
confidentialmarkupsvb_-x105.jpg	Edgar Link	pending
confidentialmarkupsvb_-x106.jpg	Edgar Link	pending
confidentialmarkupsvb_-x107.jpg	Edgar Link	pending
confidentialmarkupsvb_-x108.jpg	Edgar Link	pending
confidentialmarkupsvb_-x109.jpg	Edgar Link	pending
confidentialmarkupsvb_-x110.jpg	Edgar Link	pending
confidentialmarkupsvb_-x111.jpg	Edgar Link	pending
confidentialmarkupsvb_-x112.jpg	Edgar Link	pending
confidentialmarkupsvb_-x113.jpg	Edgar Link	pending
confidentialmarkupsvb_-x114.jpg	Edgar Link	pending
confidentialmarkupsvb_-x115.jpg	Edgar Link	pending
confidentialmarkupsvb_-x116.jpg	Edgar Link	pending
confidentialmarkupsvb_-x117.jpg	Edgar Link	pending
confidentialmarkupsvb_-x118.jpg	Edgar Link	pending
confidentialmarkupsvb_-x119.jpg	Edgar Link	pending
confidentialmarkupsvb_-x120.jpg	Edgar Link	pending
confidentialmarkupsvb_-x121.jpg	Edgar Link	pending
confidentialmarkupsvb_-x122.jpg	Edgar Link	pending
confidentialmarkupsvb_-x123.jpg	Edgar Link	pending
confidentialmarkupsvb_-x124.jpg	Edgar Link	pending
confidentialmarkupsvb_-x125.jpg	Edgar Link	pending
confidentialmarkupsvb_-x126.jpg	Edgar Link	pending
confidentialmarkupsvb_-x127.jpg	Edgar Link	pending
exh1018directorcompensatio.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20221231.htm	Edgar Link	pending
sibn-20221231.xsd	Edgar Link	pending
sibn-ex211_12312022listxof.htm	Edgar Link	pending
sibn-ex231_pwcxconsent1231.htm	Edgar Link	pending
sibn-ex311_12312210xk.htm	Edgar Link	pending
sibn-ex312_12312210xk.htm	Edgar Link	pending
sibn-ex321_12312210xk.htm	Edgar Link	pending
sibn-20221231_cal.xml	Edgar Link	unprocessable
sibn-20221231_def.xml	Edgar Link	unprocessable
sibn-20221231_lab.xml	Edgar Link	unprocessable
sibn-20221231_pre.xml	Edgar Link	unprocessable
sibn-20221231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2023 Q1 Form 10-K Financial Statement

#000145983923000020 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2023 Q1 Form 10-K Financial Statement

#000145983923000020 Filed on March 02, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn